In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. DexCom (NasdaqGS:DXCM) is ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...

Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...

The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more affordable way to monitor their blood sugar. The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more ...

Dexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S. Glucose is a type of sugar people receive from food, and it's the ...

This week, Dexcom became the first medical device company to integrate generative AI into a continuous glucose monitor. The company added generative AI to its Stelo glucose monitor, which it began ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of ...

Dexcom DXCM recently announced an upcoming nationwide rollout of an AI-driven upgrade to its Stelo platform aimed at improving users’ understanding of glucose health and supporting long-term wellness ...